Sorrento Therapeutics (SRNE) Competitors $0.0035 0.00 (0.00%) As of 11:55 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRNE vs. PPBT, GNPX, EVOK, ALZN, ENTO, ADIL, BCTX, AIM, KZIA, and CDIOShould you be buying Sorrento Therapeutics stock or one of its competitors? The main competitors of Sorrento Therapeutics include Purple Biotech (PPBT), GENPREX (GNPX), Evoke Pharma (EVOK), Alzamend Neuro (ALZN), Entero Therapeutics (ENTO), Adial Pharmaceuticals (ADIL), Briacell Therap (BCTX), AIM ImmunoTech (AIM), Novogen (KZIA), and Cardio Diagnostics (CDIO). These companies are all part of the "pharmaceutical products" industry. Sorrento Therapeutics vs. Its Competitors Purple Biotech GENPREX Evoke Pharma Alzamend Neuro Entero Therapeutics Adial Pharmaceuticals Briacell Therap AIM ImmunoTech Novogen Cardio Diagnostics Sorrento Therapeutics (NASDAQ:SRNE) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability. Which has better earnings & valuation, SRNE or PPBT? Purple Biotech has lower revenue, but higher earnings than Sorrento Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSorrento Therapeutics$60.32M0.03-$572.84MN/AN/APurple BiotechN/AN/A-$7.24M-$0.42-1.38 Which has more volatility and risk, SRNE or PPBT? Sorrento Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Purple Biotech has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Does the media refer more to SRNE or PPBT? In the previous week, Sorrento Therapeutics' average media sentiment score of 0.00 beat Purple Biotech's score of -1.00 indicating that Sorrento Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Sorrento Therapeutics Neutral Purple Biotech Negative Do analysts rate SRNE or PPBT? Purple Biotech has a consensus price target of $33.00, suggesting a potential upside of 5,579.86%. Given Purple Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Purple Biotech is more favorable than Sorrento Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sorrento Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Purple Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is SRNE or PPBT more profitable? Sorrento Therapeutics' return on equity of 0.00% beat Purple Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Sorrento TherapeuticsN/A N/A N/A Purple Biotech N/A -14.00%-12.52% Do insiders & institutionals believe in SRNE or PPBT? 0.0% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 9.6% of Purple Biotech shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by company insiders. Comparatively, 3.0% of Purple Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryPurple Biotech beats Sorrento Therapeutics on 6 of the 11 factors compared between the two stocks. Get Sorrento Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SRNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRNE vs. The Competition Export to ExcelMetricSorrento TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.93M$353.18M$6.13B$10.51BDividend YieldN/AN/A5.51%4.67%P/E RatioN/AN/A85.5226.80Price / Sales0.03435.58585.10183.02Price / CashN/A22.4426.3031.10Price / BookN/A3.8513.166.63Net Income-$572.84M-$133.30M$3.30B$276.44M7 Day PerformanceN/A5.32%4.71%2.93%1 Month PerformanceN/A21.09%8.36%9.95%1 Year PerformanceN/A19.42%87.42%39.62% Sorrento Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRNESorrento Therapeutics0.9626 of 5 stars$0.00flatN/A-2.8%$1.93M$60.32M0.00800Gap DownPPBTPurple Biotech1.4319 of 5 stars$0.59-1.7%$33.00+5,498.0%-87.7%$7.70MN/A-1.4020Positive NewsShort Interest ↑GNPXGENPREX0.9178 of 5 stars$0.17-6.4%N/A-41.7%$7.67MN/A0.0020Negative NewsShort Interest ↑EVOKEvoke Pharma0.8629 of 5 stars$4.82-1.6%N/A-10.9%$7.64M$10.25M-1.884Short Interest ↓ALZNAlzamend Neuro2.3735 of 5 stars$2.36-2.1%$42.00+1,679.7%-82.9%$7.57MN/A0.004ENTOEntero TherapeuticsN/A$4.96+4.4%N/A+134.0%$7.55MN/A0.009News CoverageGap DownADILAdial Pharmaceuticals3.3796 of 5 stars$0.33-3.4%$8.00+2,306.7%-58.7%$7.51MN/A-0.3220BCTXBriacell Therap1.9252 of 5 stars$10.83-1.9%$320.00+2,854.8%-91.0%$7.48MN/A-0.138News CoverageAIMAIM ImmunoTechN/A$2.74+2.2%$275.00+9,936.5%N/A$7.42M$121K-5.8320KZIANovogen3.2671 of 5 stars$7.47+1.9%$14.00+87.4%-69.2%$7.38M$1.51M0.0012News CoveragePositive NewsCDIOCardio Diagnostics0.3724 of 5 stars$4.00-1.7%N/A-35.2%$7.18M$19.51K0.001Gap Up Related Companies and Tools Related Companies Purple Biotech Competitors GENPREX Competitors Evoke Pharma Competitors Alzamend Neuro Competitors Entero Therapeutics Competitors Adial Pharmaceuticals Competitors Briacell Therap Competitors AIM ImmunoTech Competitors Novogen Competitors Cardio Diagnostics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRNE) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sorrento Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sorrento Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
